

# Appointment of Trustees

November 2025 | Reference: FAQACH



# About LifeArc

LifeArc is a pioneering life sciences organisation with a distinguished mission to transform scientific discoveries into tangible health benefits for patients. LifeArc is leading the way for change in rare diseases and supporting promising initiatives in antimicrobial resistance in global health.

Established as a not-for-profit organisation, LifeArc is dedicated to fostering innovation and advancing life sciences by providing funding, expertise, and collaborative partnerships. Its core focus lies in bridging the gap between bench to bedside, ensuring that groundbreaking advancements in medicine reach those who need them most.

With a robust commitment to driving progress in vital areas such as drug development, diagnostics, and biomedical technology, LifeArc actively seeks out and invests in pre-clinical research initiatives. More recently the organisation



is broadening its focus to engage in collaborative projects in clinical research with the aim to drive patient impact in rare diseases and resistant infections within the next three to five years.

LifeArc also plays a crucial role in advocacy and education within the biomedical sector, striving to enhance the overall ecosystem for research and development. By engaging with policymakers, healthcare professionals, and the broader community, LifeArc aims to raise awareness of the vital importance of translating scientific research into effective treatments and interventions.



## Discovery

## Pre-clinical

- Post-academia, pre-venture capital, proof of concept
- Designing molecules/assays
- Navigating development
- Protecting innovation

## Clinical

- Pre- and early clinical trials
- Clinical proof of concept
- Regulatory submissions
- Building cohorts
- Demonstrating safety and efficacy

## Market approval

# Strategic vision

The strategic vision of LifeArc is deeply rooted in scientific excellence and a profound understanding of patient needs, positioning the organisation as a leader in the movement to transform health innovations into real-world solutions. LifeArc's integrated approach ensures that it remains at the forefront of medical research while maintaining a strong commitment to ethical practices and transparency.

---

We're focused on delivering what patients tell us they most need, whether that's a transformative new drug, diagnostic, device or digital solution.

---

We partner with organisations and researchers already doing incredible work to provide:



### Investment

- Grant funding, partnerships and ventures investment



### Expert scientific support

- Drug discovery, and antibody discovery and humanisation


We have 5 translational challenge areas:

Childhood Cancer

Rare Respiratory and Rare Disease

Neurodegeneration

Global Health



# Childhood Cancer

We're focused on better treatments, better trials and better decisions for the 400,000+ children and young adults diagnosed with childhood cancer globally each year.

---



## Better treatments

- Develop bespoke, child-first therapeutics targeting the unique drivers of childhood cancer.
- Address 'undruggable' causes, especially in cancers with poor survival.



## Better trials

- Test treatments in disease-specific, adaptive platform trials that meet regulatory requirements and are accessible to children and young people.
- Reduce duplication in early cell and gene therapy trials by uniting the community.
- Define regulatory pathways for treatments that may not be commercially viable.
- Partner with industry to rescue deprioritised therapeutics that show promise for children.




## Better decisions

- Promote less invasive monitoring to reduce the psychological and physical impact of a diagnosis on children and their families.
- Pioneer regulatory routes for AI-assisted decision-making.

# Chronic and Rare Respiratory Disease

We're working to reduce the time it takes to receive an accurate diagnosis, accelerate development of disease modifying treatments, improve management of resistant infections and build a connected ecosystem that delivers lasting impact.

---



## Right diagnosis

- Detect and diagnose chronic lung diseases earlier, to speed up the route to specialist care.
- Predict severe disease and exacerbations.
- Monitor infection reliably to improve treatment strategies for patients.



## Better treatments

- Develop novel therapies for resistant infections and rare respiratory.
- Design better clinical trials and platform studies for childhood bronchiectasis.
- Support new approaches to improve lung inflammation.



## Scale and legacy

- Fund and develop an ecosystem that works together to develop innovations and improve patient lives.
- Support our hub networks to foster innovation and implement transformative clinical trials.

# Motor Neuron Disease (MND) and Rare Dementias

We're channelling support and funding into research areas for rare neurodegenerative diseases that have received limited attention. We're also using LifeArc's unique capabilities to contribute to the ecosystem.

---



## Early detection and diagnosis

- Use patient data to predict disease earlier.
- Develop and validate biomarkers to measure disease progression.
- Stratify patients to ensure the right drugs are tested in the right people.



## Therapeutic development

- Develop and progress our portfolio of novel targets.
- Improve early clinical pharmacology to validate pathways and demonstrate target engagement to help inform and de-risk clinical trials.



## Ecosystem involvement

- Collectively develop better cell models with the research community.
- Allow patients to shape research priorities and engage in research.
- Share our translational science expertise with the ecosystem.



# Rare Disease


We're supporting an ecosystem that removes barriers to progress across rare disease.

---



## Strengthen capability

- Create and support networks across the UK ecosystem to amplify visibility, attract partnerships, build specialised skills and foster collaboration.



## Accelerate product development

- Manage numerous funding schemes (preclinical and clinical).
- Explore a joint venture to reactivate stalled assets.
- Partner on promising rare projects.



## Address patient access

- Influence health policy.
- Explore alternative access models.

# Global Health – Infection

We're focusing on preventing and controlling resistant infections in highly impacted populations worldwide.

We want to strengthen our position as a global health leader and create meaningful progress in how innovations are developed, scaled and sustained.



## Accelerate development of innovations

- Invest in antimicrobial development.
- Invest in cost-effective and rapid diagnostic tools.
- Support access and affordability of therapeutics and diagnostics.



## Inform clinical practice and better stewardship

- Support smarter use of existing treatments through better stewardship.
- Support adoption of diagnostic tools and data systems.



## Nurture a sustainable innovation ecosystem

- Support capacity strengthening to mitigate resistant infections.
- Integrate community, patient and caregiver perspectives into solutions.

# Our Board

As a UK registered and self-funded charity, we focus on improving the lives of patients. Our board of Trustees offers expertise in biomedical sciences, biotech and pharma, finance, law and medicine. The Board governs our functions within our constitution and the achievement of our charitable objects.

## Articles of association

Our charitable objects, as set out in our Articles of Association, are:

- To promote the public benefit by improving human health and medical research, in particular by assisting the progress of the scientific discoveries and new technologies arising from research into therapeutic treatments, drugs, diagnostics, other technologies or information resources.
- To work with industry, charities, universities, the health service and other relevant bodies as well as conducting its own research and development as needed to accelerate the progress of these discoveries and technologies to the stage at which they are (i) capable of being made generally available to the medical profession and the public for practical application for the improvement of health and/or (ii) are transferred or licensed to a third party to progress development of such discoveries or technologies towards such goals.

Our performance and achievements to fulfil our charitable objects are published yearly. To read our latest annual account, please [click here](#).

## Management team

The Executive Management Team is responsible for the day-to-day running of the charity under authority delegated by the Board of Trustees. The team, under the leadership of the CEO, proposes to the Board where the charity should invest its time, money and expertise. It is also responsible for developing the financial and operational plans for Board approval and monitoring financial performance.

For profiles of the full LifeArc Board of Trustees and Executive Team and further information please [click here](#).

## Funding

LifeArc funds aim to progress promising medical research. Our charitable model allows us to invest in risky projects or where commercial returns may be low.

You can find out more about our [funding here](#).

# The roles

As LifeArc embarks on the next phase of its ambitious strategy to accelerate medical innovation and transform patient outcomes, the organisation is seeking to appoint three new Non-Executive Trustees.

These individuals will join a highly experienced and committed Board at a pivotal time, helping to guide LifeArc's strategic direction and ensure it fulfils its mission to turn cutting-edge science into tangible benefits for patients. With several forthcoming retirements creating space for fresh perspectives and new expertise, this is an exceptional opportunity for trustees who are deeply engaged, purpose-driven, and eager to play an active role in shaping the future of one of the UK's most impactful life sciences charities.



We are looking to appoint Trustees with the following skillsets and experience to join the Board:

## Qualified accountant

This person will become the new Audit and Risk Management Committee (ARMC) chair, and should have experience of chairing a committee, ideally the ARMC.

## Drug discovery and AI usage

## Clinical trials

## Data science

## Patient advocacy

# Person specification

The successful candidates for these roles will be able to demonstrate the experience and skillsets listed above, as well as all or most of the following:

- Independent and confident contributor, both within and outside the Board.
- Ability to bring constructive challenge, enthusiasm and support for the executive team, while also holding them to account.
- Motivated by the opportunity presented by LifeArc to make a major impact.
- Respected in their own field and possessing demonstrable a strong professional network.
- Able to commit time and energy to the role and to engage with the organisation and its activity.
- Demonstrates ability to think strategically and to contribute in their own field while recognising the distinction between an executive and non-executive role.
- High personal standards and committed to enhancing diversity and inclusion.
- Comfortable with the opportunity to be an ambassador for LifeArc and represent the charity.
- Ideally previous experience of non-executive Board role/s or otherwise capable of demonstrating they are “board ready.”
- High potential candidates will be those with chairing experience of small or large boards including leading Boards of Trustees for a charity.

---

LifeArc is committed to the principles and practices of equal opportunities and to encouraging the establishment of a diverse workforce and Board of Trustees. It is our policy to employ individuals on the basis of their suitability for the work to be performed and their potential for development, regardless of age, sex, race, colour, nationality, ethnic or national origin, disability, marital status, pregnancy or maternity, sexual orientation, gender reassignment, religion, or belief. This includes creating a culture that fully reflects our commitment to equal opportunities for all.




Our work transforms  
medical innovation  
into patient benefit.

# Terms of appointment

Trustees are appointed to the Board of LifeArc for terms of three years, renewable for up to three terms.

The envisaged time commitment for these roles is between 1-1.5 days per month. All Trustees are expected to join at least one sub-committee.



## 2026 group board meeting dates:

17 March

23 June

7 and 8 October

10 December

## How to apply

Saxton Bampfylde Ltd is acting as an employment agency adviser to LifeArc on this appointment.

Candidates should apply for this role through our website at [www.saxbam.com/appointments](http://www.saxbam.com/appointments) using code FAQACH.

Click on the 'apply' button and follow the instructions to upload a CV and cover letter and complete the online equal opportunities monitoring\* form.

The closing date for applications is midday on Friday 12 December 2025.

\*The equal opportunities monitoring online form will not be shared with anyone involved in assessing your application. Please complete as part of the application process.

